X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6181) 6181
deoxycytidine - analogs & derivatives (5799) 5799
science & technology (5600) 5600
life sciences & biomedicine (5331) 5331
oncology (3278) 3278
female (2949) 2949
deoxycytidine - pharmacology (2924) 2924
deoxycytidine - administration & dosage (2400) 2400
male (2330) 2330
gemcitabine (2195) 2195
animals (2109) 2109
pharmacology & pharmacy (2061) 2061
middle aged (1974) 1974
cell line, tumor (1877) 1877
aged (1777) 1777
adult (1538) 1538
antineoplastic combined chemotherapy protocols - therapeutic use (1494) 1494
deoxycytidine - therapeutic use (1464) 1464
cancer (1359) 1359
mice (1348) 1348
chemotherapy (1322) 1322
pancreatic neoplasms - drug therapy (1234) 1234
antimetabolites, antineoplastic - pharmacology (1161) 1161
pancreatic cancer (1137) 1137
deoxycytidine - adverse effects (1009) 1009
treatment outcome (996) 996
pancreatic neoplasms - pathology (962) 962
capecitabine (913) 913
fluorouracil - analogs & derivatives (843) 843
antineoplastic combined chemotherapy protocols - adverse effects (809) 809
dose-response relationship, drug (803) 803
antineoplastic agents - pharmacology (800) 800
apoptosis - drug effects (731) 731
antimetabolites, antineoplastic - therapeutic use (707) 707
research (689) 689
medicine & public health (657) 657
apoptosis (647) 647
cell proliferation - drug effects (646) 646
antimetabolites, antineoplastic - administration & dosage (633) 633
pharmacology/toxicology (616) 616
fluorouracil - administration & dosage (610) 610
care and treatment (604) 604
drug synergism (586) 586
drug resistance, neoplasm (578) 578
lung neoplasms - drug therapy (570) 570
aged, 80 and over (564) 564
pancreatic neoplasms - metabolism (557) 557
mice, nude (546) 546
cell survival - drug effects (534) 534
analysis (529) 529
drug administration schedule (525) 525
xenograft model antitumor assays (522) 522
deoxycytidine - pharmacokinetics (515) 515
antineoplastic agents (502) 502
cancer research (501) 501
tumor cells, cultured (481) 481
antimitotic agents (470) 470
antineoplastic combined chemotherapy protocols - pharmacology (467) 467
biochemistry & molecular biology (456) 456
drug therapy (454) 454
deoxycytidine - metabolism (453) 453
antineoplastic combined chemotherapy protocols - administration & dosage (452) 452
tumors (446) 446
carcinoma, non-small-cell lung - drug therapy (434) 434
cisplatin - administration & dosage (425) 425
adenocarcinoma - drug therapy (424) 424
breast neoplasms - drug therapy (420) 420
time factors (415) 415
disease-free survival (413) 413
antimetabolites, antineoplastic - adverse effects (410) 410
metastasis (399) 399
azacitidine - analogs & derivatives (396) 396
antineoplastic agents - therapeutic use (390) 390
survival analysis (390) 390
cancer therapies (389) 389
azacitidine - pharmacology (387) 387
health aspects (386) 386
neoplasms - drug therapy (375) 375
gene expression (373) 373
deoxycytidine - chemistry (368) 368
pancreatic neoplasms - genetics (364) 364
cell line (360) 360
dna methylation (356) 356
breast cancer (352) 352
neoplasm metastasis (350) 350
clinical trials (340) 340
cell biology (334) 334
survival rate (334) 334
pharmacology (329) 329
gene expression regulation, neoplastic - drug effects (321) 321
drug resistance (317) 317
neoplasm staging (314) 314
research article (310) 310
dosage and administration (307) 307
prognosis (306) 306
phosphorylation (305) 305
fluorouracil - therapeutic use (298) 298
lung neoplasms - pathology (296) 296
mice, inbred balb c (291) 291
fluorouracil - adverse effects (287) 287
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7182) 7182
Japanese (64) 64
Chinese (56) 56
French (18) 18
Russian (18) 18
German (10) 10
Spanish (10) 10
Italian (4) 4
Hungarian (2) 2
Portuguese (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Korean (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2003, Volume 2, Issue 10, pp. 971 - 984
Journal Article
Investigational new drugs, ISSN 1573-0646, 06/2014, Volume 32, Issue 5, pp. 825 - 837
The G1 restriction point is critical for regulating the cell cycle and is controlled by the Rb pathway (CDK4/6-cyclin D1-Rb-p16/ink4a). This pathway is... 
Medicine & Public Health | Cell cycle | Oncology | In vivo antitumor activity | Pharmacology/Toxicology | Combination therapy | LY2835219 | Kinase inhibitor | CDK4/6 inhibitor | Cdk4/6 inhibitor | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Neoplasms - metabolism | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Deoxycytidine - therapeutic use | Aminopyridines - therapeutic use | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Retinoblastoma Protein - metabolism | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Protein Kinase Inhibitors - therapeutic use | Aminopyridines - pharmacology | Retinoblastoma Protein - antagonists & inhibitors | Cell Line, Tumor | Benzimidazoles - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | G1 Phase Cell Cycle Checkpoints - drug effects | Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Dosage and administration | Research | Gemcitabine | Studies | Protein expression | Inhibitor drugs | Kinases | Cancer therapies | Analysis | CDK4 | Preclinical Studies | 6 inhibitor
Journal Article
Clinical cancer research, ISSN 1557-3265, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2004, Volume 96, Issue 10, pp. 739 - 749
Journal Article
Cancer discovery, ISSN 2159-8290, 2012, Volume 2, Issue 6, pp. 524 - 539
Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models and WEE1 inhibitors are being explored as potential cancer therapies.... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Protein Kinases - metabolism | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Apoptosis - drug effects | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Quinolines - pharmacology | Tumor Suppressor Protein p53 - genetics | Breast Neoplasms - metabolism | Cell Cycle Proteins - antagonists & inhibitors | DNA-Binding Proteins - metabolism | Deoxycytidine - therapeutic use | Cyclins - metabolism | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Pyrazoles - pharmacology | Cell Line | Pyrimidinones | Thiophenes - pharmacology | Pyrimidines - pharmacology | Mice, SCID | Breast Neoplasms - drug therapy | Enhancer of Zeste Homolog 2 Protein | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Polycomb Repressive Complex 2 | Urea - therapeutic use | Animals | Mitosis - drug effects | Tumor Burden - drug effects | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Checkpoint Kinase 1 | Mice | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | S Phase - drug effects | Thiazoles - pharmacology | Deoxycytidine - analogs & derivatives | Urea - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Cancer research (Chicago, Ill.), ISSN 1538-7445, 04/2013, Volume 73, Issue 12, pp. 3683 - 3691
Replication stress and DNA damage activate the ATR-Chk1 checkpoint signaling pathway that licenses repair and cell survival processes. In this study, we... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Protein Kinases - metabolism | Protein Kinases - genetics | Humans | Ovarian Neoplasms - pathology | Cell Survival - genetics | Deoxycytidine - pharmacology | Immunoblotting | Sulfones - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | RNA Interference | BRCA1 Protein - metabolism | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Phosphorylation - drug effects | cdc25 Phosphatases - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Cell Survival - drug effects | Topotecan - pharmacology | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Signal Transduction - genetics | cdc25 Phosphatases - genetics | Ataxia Telangiectasia Mutated Proteins | Cisplatin - pharmacology | Pyrimidines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerases - metabolism | BRCA2 Protein - metabolism | Signal Transduction - drug effects | Cell Line, Tumor | Benzimidazoles - pharmacology | Checkpoint Kinase 1 | Pyrazines - pharmacology | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | homologous recombination | ovarian cancer | Poly(ADP-ribose) polymerase | veliparib | gemcitabine | BRCA1 | cisplatin | BRCA2 | topotecan
Journal Article
Clinical cancer research, ISSN 1557-3265, 04/2006, Volume 12, Issue 8, pp. 2640 - 2646
Purpose: Tumor necrosis factor-related apoptosis–inducing ligand (TRAIL/Apo2L) exhibits potent antitumor activity on systemic administration in nonhuman... 
apoptosis | TRAIL | primary human hepatocytes | chemotherapy | in-vivo | tumoricidal activity | monoclonal-antibody | hepatocellular-carcinoma cells | human hepatocytes | receptor | death | nf-kappa-b | family | apoptosis-inducing ligand | Life Sciences & Biomedicine | Oncology | Science & Technology | Immunohistochemistry | Apoptosis Regulatory Proteins - pharmacology | Apoptosis - drug effects | Gene Expression - genetics | Humans | Tumor Necrosis Factor-alpha - genetics | GPI-Linked Proteins | Apoptosis - genetics | Deoxycytidine - pharmacology | Hepatocytes - metabolism | Receptors, TNF-Related Apoptosis-Inducing Ligand | Organoplatinum Compounds - pharmacology | Receptors, Tumor Necrosis Factor, Member 10c | Dose-Response Relationship, Drug | Tumor Necrosis Factor Decoy Receptors | Hepatocytes - cytology | TNF-Related Apoptosis-Inducing Ligand | Time Factors | Apoptosis Regulatory Proteins - genetics | Antineoplastic Agents - pharmacology | Hepatocytes - drug effects | Camptothecin - analogs & derivatives | Receptors, Tumor Necrosis Factor - genetics | Receptors, Tumor Necrosis Factor - metabolism | Cell Survival - drug effects | Membrane Glycoproteins - pharmacology | Cells, Cultured | Etoposide - pharmacology | Cisplatin - pharmacology | Recombinant Proteins - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Membrane Glycoproteins - genetics | Tumor Necrosis Factor-alpha - pharmacology | Cell Line, Tumor | Fluorouracil - pharmacology | Camptothecin - pharmacology | Deoxycytidine - analogs & derivatives
Journal Article
Clinical cancer research, ISSN 1557-3265, 10/2005, Volume 11, Issue 20, pp. 7508 - 7515
Purpose: BRCA2, FANCC , and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to... 
BRCA1, BRCA2 | Xenograft models | DNA damage and repair mechanisms | Pharmacogenetics/pharmacogenomics | Gastrointestinal cancers: other | Life Sciences & Biomedicine | Oncology | Science & Technology | Paclitaxel - pharmacology | Apoptosis - drug effects | Cross-Linking Reagents - pharmacology | Humans | Deoxycytidine - pharmacology | Chlorambucil - pharmacology | Fanconi Anemia Complementation Group C Protein - genetics | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Caspases - metabolism | Fanconi Anemia Complementation Group G Protein - genetics | Time Factors | Cross-Linking Reagents - therapeutic use | Fanconi Anemia Complementation Group G Protein - deficiency | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Melphalan - pharmacology | Cell Survival - drug effects | Fanconi Anemia Complementation Group Proteins - deficiency | Mitomycin - therapeutic use | Pancreatic Neoplasms - pathology | Fanconi Anemia Complementation Group Proteins - genetics | Etoposide - pharmacology | Pancreatic Neoplasms - genetics | Cisplatin - pharmacology | Xenograft Model Antitumor Assays - methods | Mitomycin - pharmacology | Animals | Mice, Nude | Cell Line, Tumor | Fanconi Anemia Complementation Group C Protein - deficiency | BRCA2 Protein - deficiency | Fluorouracil - pharmacology | Mice | Vinblastine - pharmacology | Mutation | Cell Cycle - drug effects | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology
Journal Article
Antiviral research, ISSN 0166-3542, 02/2016, Volume 126, pp. 69 - 80
Journal Article